Clinical trials: Treatment-resistant Depression (TRD)
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression
The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation.
- Trial name
- RMTSECT2 (NCT07324070)
- Testing
- Electroconvulsive therapy, Transcranial Magnetic Stimulation
- Where
- Czechia
- Volunteers
- 50 people
- Sponsor
- Charles University, Czech Republic
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Treatment Resistant Depression (TRD)
Treatment Resistant Depression and Vagus Nerve Stimulation
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments.
- Trial name
- DepVNS (NCT05952674)
- Testing
- Vagus Nerve Stimulation (VNS), Best Medical Treatment
- Where
- 24 sites in France
- Volunteers
- 166 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation
Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression
In recent years, research on the effectiveness of transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (RTD) has been steadily increasing.
- Conditions
- Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation, Accelerated Protocol, Intermittent Theta Burst Stimulation
- Trial name
- NCT07264452
- Testing
- Transcranial Magnetic Stimulation with figure-eight coil
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Treatment-resistant Depression (TRD)
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions.
- Trial name
- PSI-GROUP (NCT07737990)
- Testing
- Group integration therapy
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- Joshua Rosenblat
Treatment-resistant Depression (TRD)
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD).
- Trial name
- KIND-PR (NCT07369102)
- Testing
- Esketamine hydrochloride (intranasal), Integration Therapy
- Where
- 2 sites in Puerto Rico
- Volunteers
- 20 people
- Sponsor
- University of Puerto Rico
Treatment Resistant Depression, Major Depressive Disorder
pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression
Investigators aim to evaluate the safety and efficacy of pBFS-guided rTMS therapy targeting DMPFC for patients with treatment-resistant depression
- Trial name
- NCT05948839
- Testing
- active rTMS treatment
- Where
- 3 sites in China
- Volunteers
- 170 people
- Sponsor
- Changping Laboratory
Treatment Resistant Depression (TRD)
Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing
Ketamine is a medicine used in psychiatry for treatment-resistant depression. This study compares two ways of framing ketamine treatment: a psychedelic framing and a biomedical framing.
- Trial name
- KetSet (NCT07824973)
- Testing
- Psychedelic framing, Biomedical framing
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Valdemar Landgren
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in…
- Trial name
- NCT07217223
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Accelerated iTBS for Major Depression
Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments.
- Trial name
- AIM-D (NCT07603804)
- Testing
- Accelerated Intermittent Theta Burst Stimulation (iTBS)
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University - Cerrahpasa
Treatment Resistant Depression
IV Ketamine vs. IN Esketamine for MDD TRD
The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations.
- Trial name
- NCT06488586
- Testing
- Low dose IV Ketamine vs. IN Esketamine
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Gustavo Vazquez
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Major Depressive Disorder, Treatment Resistant Depression
Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression
According to the World Health Organization, MDD is attributed as the leading cause of disability worldwide, leaving 300 million individuals affected.
- Trial name
- NCT03977038
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment-Resistant Depression, Treatment-resistant Depression (TRD)
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
The goal of this clinical trial is to evaluate the safety and initial effectiveness of Magnetic Resonance-guided focused ultrasound neuromodulation using the Next Generation Dome Helmet (NGDH) device in patients with…
- Trial name
- NCT07094789
- Testing
- Next Generation Dome Helmet (NGDH)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sunnybrook Health Sciences Centre
Major Depressive Disorder
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)
To confirm the safety and efficacy of the NCP System in treating patients in a nmajor depressive episode.
- Trial name
- NCT00533832
- Testing
- vagus nerve stimulation (VNS)
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Cyberonics, Inc.
Treatment Resistant Depression (TRD)
Comparison of Different Acceleration Modes of Transcranial Magnetic Stimulation
To compare the efficacy and safety of 6 times a day, 10 times a day acceleration mode and sham stimulation intervention for TRD, and to explore the antidepressant mechanism of accelerated mode, so as to provide a more simple and…
- Trial name
- NCT06881030
- Testing
- Noninvasive transcranial magnetic stimulation was administered six times daily, Noninvasive transcranial magnetic stimulation was administered 10 times daily
- Volunteers
- 45 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an…
- Trial name
- SPARC-TMS (NCT07227103)
- Testing
- Neuronavigated robotic-enabled TMS, NRX-101
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroRx, Inc.
Treatment Resistant Depression (TRD), Inflammation
TACS on High-inflammatory and Refractory Depression
This study is a randomized controlled trial with a duration of 12 weeks (4 weeks of intervention + 8 weeks of follow-up). The participants are patients with treatment-resistant depression (TRD) and high inflammatory activity…
- Trial name
- NCT06812923
- Testing
- transcranial Alternating Current Stimulation (tACS)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Anding Hospital
Treatment Resistant Depression (TRD)
Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.
Major depressive disorder (MDD) is a major contributor to impaired health worldwide. Initial antidepressant treatment of MDD does not lead to response in up to 50 % of patients.
- Trial name
- DARE (NCT07843927)
- Testing
- Dehydroepiandrosterone (DHEA)
- Where
- 9 sites in Germany
- Volunteers
- 320 people
- Sponsor
- Charite University, Berlin, Germany